Relmada Therapeutics is a company developed to provide therapy for the treatment of chronic pain. To make this work, the company put products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. They use five products d-Methadone, N-methyl-D-aspartate, topical mepivacaine, oral buprenorphine and LeviCap Er. This company has issued a temporary restraining order against Laidlaw & Company. The company claims that Laidlaw and Company continues to disseminate false and misleading proxy materials. Relmada claims that Laidlaw provided false information in attempt to take over their company. Laidlaw was an investment banker to Relmada. Laidlaw has a reputation for customer complaints, regulatory sanctions and monetary penalties. Relmada do not believe that it is in their stockholders’ best interest to give effective control of the Company to Laidlaw.
Laidlaw is an investment brokerage firm. They offer personalized investment advice and skillful execution to private and public institutions. The company was started in 1942 becoming one of the first investment banks. The company was started by Devid Heran adn James Less. Matthew Eitner is currently the CEO of LAidlaw & Company. He started with the firm in 2010. James Ahern also now have a huge role at Laidlaw & Company. He is Managing Partner and Head of Capital Markets and started in 2010 as well. The office networks with offices in the United States and Europe. Both men serve in the UK location. This company has been trusted for 170 years and has over 150 employees. They give corporate clients the financial flexibility to grow by raising the capital through their retail sales force.In 2011, Laidlaw launched capital market, research and banking initiatives in health care, biotechnology, pharmaceuticals and medical devices. They added metals, mining and natural resources to its investment banking and capital markets strategy in 2012. This company continues to grow.